Last year, Angelini Pharma entered into a strategic partnership with Cureverse, a Korean spin-off of the Korean Institute of Science and Technology, which is developing small molecules with broad CNS applications. Consequently, Angelini’s brain health pipeline now includes diversified and modern therapeutic modalities ranging from innovative small molecule compounds to biologics and anti-sense oligonucleotides. The Company researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health. Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Optimizing brain health across the life course: WHO position paper.